An overview of new GLP-1 receptor agonists for type 2 diabetes

Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong Min Liu

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Introduction: The increasing prevalence of type 2 diabetes mellitus (T2DM) and the eventual need for multiple medications in most patients stimulated the development of new drug classes to reduce plasma glucose levels. The GLP-1 receptor agonists (GLP-1RAs) are established as an option for treatment of T2DM after metformin. They are also effective in reducing body weight but current GLP-1RAs have to be given by subcutaneous injection daily or once weekly.Areas covered: This review focuses on the new GLP-1RAs currently undergoing development, some of which require less frequent subcutaneous administration and others that are being developed in oral formulations that may favor patient adherence.Expert opinion: The new GLP-1RAs may have the benefit of requiring less frequent subcutaneous dosing or being active by oral administration. However, cardiovascular outcome trials have shown that DPP4 inhibitors are neutral for cardiovascular events and the first cardiovascular outcome trial with lixisenatide reported similar results, whereas the trial with the SGLT2 inhibitor empagliflozin showed a reduction in cardiovascular events. These findings in patients with high cardiovascular risk may favor the use of SGLT2 inhibitors as a second line treatment after metformin but there should still be an important role for novel GLP-1RAs, especially when weight reduction is required.

Original languageEnglish
Pages (from-to)145-158
Number of pages14
JournalExpert Opinion on Investigational Drugs
Volume25
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Type 2 Diabetes Mellitus
Metformin
Expert Testimony
Subcutaneous Injections
Patient Compliance
Oral Administration
Weight Loss
Body Weight
Glucagon-Like Peptide-1 Receptor
Glucose
Therapeutics
Pharmaceutical Preparations

Keywords

  • Efpeglenatide
  • GLP-1
  • GLP-1 receptor agonist
  • glymera
  • semaglutide
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

An overview of new GLP-1 receptor agonists for type 2 diabetes. / Tomlinson, Brian; Hu, Miao; Zhang, Yuzhen; Chan, Paul; Liu, Zhong Min.

In: Expert Opinion on Investigational Drugs, Vol. 25, No. 2, 01.02.2016, p. 145-158.

Research output: Contribution to journalArticle

Tomlinson, Brian ; Hu, Miao ; Zhang, Yuzhen ; Chan, Paul ; Liu, Zhong Min. / An overview of new GLP-1 receptor agonists for type 2 diabetes. In: Expert Opinion on Investigational Drugs. 2016 ; Vol. 25, No. 2. pp. 145-158.
@article{827c4023d29641b2a1dd9682fbf72d4c,
title = "An overview of new GLP-1 receptor agonists for type 2 diabetes",
abstract = "Introduction: The increasing prevalence of type 2 diabetes mellitus (T2DM) and the eventual need for multiple medications in most patients stimulated the development of new drug classes to reduce plasma glucose levels. The GLP-1 receptor agonists (GLP-1RAs) are established as an option for treatment of T2DM after metformin. They are also effective in reducing body weight but current GLP-1RAs have to be given by subcutaneous injection daily or once weekly.Areas covered: This review focuses on the new GLP-1RAs currently undergoing development, some of which require less frequent subcutaneous administration and others that are being developed in oral formulations that may favor patient adherence.Expert opinion: The new GLP-1RAs may have the benefit of requiring less frequent subcutaneous dosing or being active by oral administration. However, cardiovascular outcome trials have shown that DPP4 inhibitors are neutral for cardiovascular events and the first cardiovascular outcome trial with lixisenatide reported similar results, whereas the trial with the SGLT2 inhibitor empagliflozin showed a reduction in cardiovascular events. These findings in patients with high cardiovascular risk may favor the use of SGLT2 inhibitors as a second line treatment after metformin but there should still be an important role for novel GLP-1RAs, especially when weight reduction is required.",
keywords = "Efpeglenatide, GLP-1, GLP-1 receptor agonist, glymera, semaglutide, type 2 diabetes mellitus",
author = "Brian Tomlinson and Miao Hu and Yuzhen Zhang and Paul Chan and Liu, {Zhong Min}",
year = "2016",
month = "2",
day = "1",
doi = "10.1517/13543784.2016.1123249",
language = "English",
volume = "25",
pages = "145--158",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - An overview of new GLP-1 receptor agonists for type 2 diabetes

AU - Tomlinson, Brian

AU - Hu, Miao

AU - Zhang, Yuzhen

AU - Chan, Paul

AU - Liu, Zhong Min

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Introduction: The increasing prevalence of type 2 diabetes mellitus (T2DM) and the eventual need for multiple medications in most patients stimulated the development of new drug classes to reduce plasma glucose levels. The GLP-1 receptor agonists (GLP-1RAs) are established as an option for treatment of T2DM after metformin. They are also effective in reducing body weight but current GLP-1RAs have to be given by subcutaneous injection daily or once weekly.Areas covered: This review focuses on the new GLP-1RAs currently undergoing development, some of which require less frequent subcutaneous administration and others that are being developed in oral formulations that may favor patient adherence.Expert opinion: The new GLP-1RAs may have the benefit of requiring less frequent subcutaneous dosing or being active by oral administration. However, cardiovascular outcome trials have shown that DPP4 inhibitors are neutral for cardiovascular events and the first cardiovascular outcome trial with lixisenatide reported similar results, whereas the trial with the SGLT2 inhibitor empagliflozin showed a reduction in cardiovascular events. These findings in patients with high cardiovascular risk may favor the use of SGLT2 inhibitors as a second line treatment after metformin but there should still be an important role for novel GLP-1RAs, especially when weight reduction is required.

AB - Introduction: The increasing prevalence of type 2 diabetes mellitus (T2DM) and the eventual need for multiple medications in most patients stimulated the development of new drug classes to reduce plasma glucose levels. The GLP-1 receptor agonists (GLP-1RAs) are established as an option for treatment of T2DM after metformin. They are also effective in reducing body weight but current GLP-1RAs have to be given by subcutaneous injection daily or once weekly.Areas covered: This review focuses on the new GLP-1RAs currently undergoing development, some of which require less frequent subcutaneous administration and others that are being developed in oral formulations that may favor patient adherence.Expert opinion: The new GLP-1RAs may have the benefit of requiring less frequent subcutaneous dosing or being active by oral administration. However, cardiovascular outcome trials have shown that DPP4 inhibitors are neutral for cardiovascular events and the first cardiovascular outcome trial with lixisenatide reported similar results, whereas the trial with the SGLT2 inhibitor empagliflozin showed a reduction in cardiovascular events. These findings in patients with high cardiovascular risk may favor the use of SGLT2 inhibitors as a second line treatment after metformin but there should still be an important role for novel GLP-1RAs, especially when weight reduction is required.

KW - Efpeglenatide

KW - GLP-1

KW - GLP-1 receptor agonist

KW - glymera

KW - semaglutide

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84957440729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957440729&partnerID=8YFLogxK

U2 - 10.1517/13543784.2016.1123249

DO - 10.1517/13543784.2016.1123249

M3 - Article

C2 - 26587691

AN - SCOPUS:84957440729

VL - 25

SP - 145

EP - 158

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 2

ER -